We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sartorius Stedim Biotech Extends Portfolio with Majority Stake in AllPure Technologies

By LabMedica International staff writers
Posted on 05 May 2014
Sartorius Stedim Biotech (SSB; Aubagne, France) has signed a contract to acquire the majority stake in the privately owned start-up AllPure Technologies LLC (New Oxford, PA, USA). AllPure Technologies designs, manufactures, and markets innovative aseptic sampling and tube sealing systems for biopharmaceutical and pharmaceutical drug developers and manufacturers; it has been on the market for 4 years, and in 2013 earned revenue of around USD 3 million, with 25 employees. SSB, dedicated to a philosophy of “turning science into solutions,” is a leading global R&D company and provider of cutting-edge equipment, products, and services for the pharmaceutical and biotech industries; it employs approx. 3,300 people, and in 2013 earned sales revenue of EUR 588.4 million.

The takeover extends SSB's portfolio for single-use bioprocessing as AllPure specializes in innovative single-use components for biopharmaceutical applications, such as aseptic sampling techniques. AllPure has launched advanced products to improve operating efficiencies, process reliability, and operator safety. Supported by numerous patent-pending technologies, its products provide quick, reliable, and safe solutions to the shortcomings of current aseptic sampling techniques. AllPure operates in a state-of-the-art facility, and complies with applicable cGMP guidelines.

“AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently. I am really looking forward to working with the AllPure team and to all that we can accomplish together,” said Reinhard Vogt, member of SSB’s Executive Board. "We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products,” said Michael Zumbrum, President of AllPure. SSB and AllPure agreed not to disclose further details of the purchase agreement.

Related Links:

Sartorius Stedim Biotech 
AllPure Technologies 



Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
LH ELISA
Luteinizing Hormone ELISA
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries